



Received on 27 December 2022; received in revised form, 12 March 2023; accepted 29 May 2023; published 01 August 2023

IN-SILICO STUDIES ON CHEMICAL CONSTITUENTS OF CALOTROPIS SPECIES

Mounika Tummalapalli ^{* 1}, V. V. Sowjanya Appala ¹, Sanny Gundugolanu ¹, Kavya Komarapu ¹, M. Trinadha Rao ² and G. Nagamani ²

Department of Pharmaceutical Chemistry ¹, Department of Pharmaceutics ², Adarsa College of Pharmacy, G. Kothapalli - 533285, Andhra Pradesh, India.

Keywords:

Calotropis, Chem sketch, Mol inspiration, Pre ADMET, Syriogenin

Correspondence to Author: Mounika Tummalapalli

Assistant Professor,
Department of Pharmaceutical
Chemistry, Adarsa College of
Pharmacy, G. Kothapalli - 533285,
Andhra Pradesh, India.

E-mail: mounikat127@gmail.com

ABSTRACT: Nowadays, the use of herbal drugs is tremendously increased due to the lesser number of side effects when compared to pure form of drugs. Herbal medicine is a complex compound with multiple synergistic mechanisms of action which modulate pathophysiological functions. Even though few herbs exhibit toxicity, they possess many therapeutic values and curative principles; one such herb is calotropis. It exists in three species that produce pharmacological effects: cardiovascular, anti-cancer, antimicrobial, anticonvulsant, and smooth muscle relaxant. In this research, 24 chemical constituents of all calotropis species were selected. The molecular properties, bioactivity scores, ADMET profile of 24 calotropis species chemical constituents were predicted using computational tools, including mol inspiration, Pre ADMET, and structures drawn using chem sketch. The results drawn from the study were compounds C₈[Syriogenin] and C₁₆[urosolic acid] exhibited good oral bioavailability, bioactivity scores, intestinal absorption, renal absorption, decreased metabolism rate by inhibiting CYP3A4 and less toxic by Ames test.

INTRODUCTION: Herbal medicine is an interdisciplinary branch that deals with herbs with medicinal values related to various branches, including botany, medicinal plant research, phytochemistry, pharmacognosy, ayurveda, natural chemistry, agriculture science, Unani medicines, biotechnology and biochemistry ¹. Herbal medicine is defined as the use of plants to prevent and treat illness or achieve good health and the drugs and tinctures used. The major use of herbal medicines is for health promotion and therapy for chronic as opposed to life-threatening conditions. Traditional medicines are widely perceived as natural and safe, that is not toxic ².

Currently, herbs are applied to treat chronic and acute conditions and various ailments and problems such as cardiovascular disease, prostate problems, depression, and inflammation and to boost the immune system, to name but a few ³. Various herbs have different pharmacological actions, including antiulcer, anticonvulsant, irregular heartbeat, anti-inflammatory insomnia, anxiety, CNS depressant effect migraine, etc. Among all the most widely used herbs, herbs belonging to the family *Asteraceae*, *Solanaceae*, *Umbelliferace*, and *Laminaceae* exhibit diverse pharmacological properties ⁴⁻⁵.

An *in-silico* study is one performed *via* stimulation on a computer. The various methods include data-based quantitative structure, activity relationship, pharmacophores, homology, models and other molecular modeling approaches, machine learning, data mining, and network analysis tools we use a computer. Such models have seen frequent use in

	<p>QUICK RESPONSE CODE</p>
	<p>DOI: 10.13040/IJPSR.0975-8232.14(8).3935-41</p>
<p>This article can be accessed online on www.ijpsr.com</p>	
<p>DOI link: http://doi.org/10.13040/IJPSR.0975-8232.14(8).3935-41</p>	

discovering and optimizing novel molecules with affinity to a target, classifying absorption, distribution, metabolism, excretion, and toxicity properties, as well as physicochemical characterization^{6, 7}. It provides a platform for screening the activity of potential therapeutics against the molecular targets, which helps to select the one with the highest potential activity for further *in-vitro* and *in-vivo* experiments focusing on only selected targets will reduce the cost for laboratory trail, that requires financial and human resources. *In-silico* studies are recently widely used to study the complexities in oxidative stress-induced pathology⁸⁻¹⁰. Based on the need for herbal medicines to treat various pathological conditions and the importance of computational tools in drug discovery, the work was carried out on one of such herbs belonging to the family *Apocynaceae*. The selected herb was *Calotropis*; it exhibits various pharmacological properties despite its toxicity due to its latex¹¹⁻¹⁴. The study aimed to perform *in-silico* screening by predicting the physicochemical and pharmacokinetic properties of chemical constituents of *Calotropis* species.

METHODOLOGY:

Chemical Structures and Generation of Smiles Notation:

Among all the *Calotropis* species, only 24 compounds are selected based on the availability of structures in Pubchem and journals. Structures of chemical constituents of *Calotropis* species about 24 (C₁-C₂₄) were drawn by using chem sketch and Chem Draw ultra 12.0 computational tools. SMILES compound (C₁-C₂₄) notations were generated using chem sketch^{15, 16}.

Prediction of Molecular Properties and Bioactivity Scores:

All the selected 24 chemical constituents of *Calotropis* species were predicted for their molecular properties and bioactivity scores by using an online web server (www.molinspiration.com) mol inspiration *in-silico* tool¹⁷. By using SMILES notation of all the selected chemical constituents (C₁-C₂₄), molecular properties and bioactivity scores were predicted.

Molecular properties including molecular weight, topological polar surface area (TPSA), number of Nitrogen atoms, number of oxygen atoms, number of OH atoms, number of NH atoms, partition coefficient (miLogP), number of rotatable bonds,

volume, number of violations. According to Lipinski rule of five. Molecular weight less than 500 Daltons, milogP less than or equal to 5, no. of Hydrogen bond donors less than or equal to 5, no. of hydrogen bond acceptor less than or equal to 10 indicates the chemical compound possesses good oral bioavailability.

Bioactivity scores SMILES notation of 24 compounds was used to predict bioactivity were predicted based on the activity scores of G-protein coupled receptor, ion channel modulator, kinase I, nuclear receptor ligand, protease I, and enzyme I. Bioactivity scores range from 0 to -0.5 indicating moderately active; bioactivity scores less than -0.5 indicates less activity; bioactivity score greater than 0, indicates highly active^{17, 18}.

Prediction of ADMET Properties: ADMET includes absorption, distribution, metabolism, elimination properties and toxicity profile of all the 24 chemical constituents (C₁-C₂₄) of *Calotropis* species were predicted by using online web server (www.PreADMET.com) PreADMET¹⁹⁻²² and admet SAR²¹⁻²³.

Prediction of Absorption, Distribution and Elimination Properties:

Pre-ADMET uses various models of *in-vivo* and *in-vitro* prediction techniques to predict oral absorption. Basic models include PSA, rapid PSA, and other complex models. Predicting tissue distribution can promote the investigation of pharmacodynamics and toxicokinetics.

Distribution prediction is mainly related to the blood-brain barrier (BBB) permeability, apparent volume of distribution (VD), and plasma protein binding (PPB). Many of these models are developed based on the three-dimensional crystal structure of albumin, which can be used for docking studies to predict the binding of molecules to albumin. Quantitative structure-activity relationship (QSAR) models are developed based on the existing data of various ligands known to bind albumin.

These computational models can accurately predict the interaction of molecules with human serum albumin.

Prediction of Metabolism and Toxicity Profile:

The metabolic process is a very complex process involving various enzyme activities and differs due to different genetic factors; we use different calculation models to predict the metabolism of some drugs. CYP enzyme affinity towards the ligands can be predicted. After carrying out the drug excretion/elimination prediction, the collected information must be integrated into the predictive model to provide a complete model to describe the substance behaviour at different stages of drug discovery and development.

Toxicity prediction with professional knowledge in computational toxicity. Groups perform QSAR

modeling through the use of toxicity databases. Drug toxicity prediction can effectively reduce the need for animal testing. Pre-ADMET can predict both systemic toxicity and the toxicity of certain organs in addition to carcinogenicity and genotoxicity.

RESULTS AND DISCUSSION:**Chemical Structures and Generation of Smiles**

Notation: All 24 selected chemical compounds C₁-C₂₄ structures were drawn, and smiles notations were generated using the computational tool chem sketch. The data was presented in **Table 1** and structures are displayed in **Fig. 1**.




FIG. 1: MOLECULAR STRUCTURES OF 24 COMPOUNDS

TABLE 1: CHEMICAL STRUCTURES OF COMPOUNDS C₁-C₂₄

Name of the Compound	Code	Name of the compound	Code
Cardenolide	C ₁	L-rhamnose	C ₁₃
Calotropin	C ₂	Amyrin acetate	C ₁₄
Voruscharin	C ₃	Beta-sitositerol	C ₁₅
Trypsin	C ₄	Urosolic acid	C ₁₆
Calactin	C ₅	Octadecenamide	C ₁₇

Gigantin	C ₆	Tyranton	C ₁₈
Thiazoline	C ₇	Pentadecane	C ₁₉
Syriogenin	C ₈	Heptadecane	C ₂₀
Uscharidin	C ₉	Erucamide (z)-docos-13-enamide	C ₂₁
Uscharin	C ₁₀	Isobutyl nonane	C ₂₂
Proceroside	C ₁₁	2,7,10-Trimethyl dodecane	C ₂₃
Calotoxin	C ₁₂	2,3-dihydro-3,5-dihydroxy -6-methyl -4H-pyran-4-one	C ₂₄

Molecular Properties and Bioactivity Scores:

The molecular properties and bioactivity scores of compounds C₁-C₂₄ were predicted using molinspiration and results were represented in **Table 2** and **Table 3**, respectively. All the compounds obeyed Lipinski rule of five except C₄. The molecular weight of all compounds ranges from 115 to 665 Daltons, mi Log P values range from -0.46 to 8.79 and no violations indicate all the derivatives exhibited good oral bioavailability and

drug-like properties. The bioactivity data revealed that all the chemical constituents were moderately active as enzyme and kinase inhibitors, inactive as ion channel modulators, and few chemical constituents displayed moderate scores towards protease inhibition, nuclear receptor inhibition, and GPCR ligand. Compounds C₁₃, C₁₈, C₂₄ showed less bioactivity scores remaining compounds exhibited moderate to high scores ranging from -0.48 to 9.58.

TABLE 2: MOLECULAR PROPERTIES OF CHEMICAL CONSTITUENTS C₁-C₂₄ OF CALOTROPIS SPECIES

Compound code	Mi Log P	TPSA	N atoms	MW	n OH	n OH NH	n Vio	N rtbs	Volume
C ₁	4.80	26.30	25	342.5	2	0	0	1	348.90
C ₂	1.15	131.76	38	532.63	9	3	1	2	480.72
C ₃	2.01	123.56	41	589.75	9	3	1	2	525.67
C ₄	2.78	240.47	48	665.75	15	9	3	16	605.62
C ₅	1.15	131.76	38	532.63	2	3	1	2	480.72
C ₆	1.82	41.93	17	237.30	4	1	0	2	228.65
C ₇	0.55	12.36	5	87.15	1	0	0	0	76.79
C ₈	1.56	86.99	28	390.52	5	3	0	1	372.68
C ₉	0.96	128.60	38	530.61	9	2	1	2	474.86
C ₁₀	2.09	123.90	41	587.74	9	2	1	2	519.73
C ₁₁	0.23	151.99	39	548.63	10	4	1	2	488.77
C ₁₂	0.42	151.99	39	548.63	10	4	1	2	488.77
C ₁₃	1.64	90.15	11	164.16	5	4	0	0	143.55
C ₁₄	8.58	26.30	34	468.77	2	0	1	2	497.56
C ₁₅	8.62	20.23	30	414.72	1	1	1	6	456.52
C ₁₆	6.79	57.53	33	456.71	3	2	1	1	471.49
C ₁₇	7.30	43.09	20	281.48	2	2	1	15	322.11
C ₁₈	0.31	37.30	8	116.16	2	1	0	2	122.62
C ₁₉	8.19	0.00	15	212.42	0	0	1	12	264.18
C ₂₀	8.79	0.00	17	240.47	0	0	1	14	297.78
C ₂₁	8.74	43.09	24	337.59	2	2	1	19	389.32
C ₂₂	6.40	0.00	13	184.37	0	0	1	8	230.15
C ₂₃	6.16	0.00	15	212.42	0	0	1	9	263.54
C ₂₄	-0.46	66.76	10	144.13	4	2	0	0	123.40

Mi Log P: lipophilicity, TPSA: topological polar surface area, n: number of, Mol. wt: molecular weight, vio: violations, rtbs: rotatable bonds.

TABLE 3: BIOACTIVITY SCORES OF COMPOUNDS C₁-C₂₄ OF CALOTROPIS SPECIES

Compound code	GPCR ligand	Ion channel modulator	Kinase Inhibitor	Nuclear receptor ligand	Protease Inhibitor	Enzyme Inhibitor
C ₁	0.11	0.12	0.48	0.39	0.17	0.63
C ₂	0.07	0.01	0.29	0.52	0.12	0.88
C ₃	0.10	0.40	0.62	0.07	0.03	0.61
C ₄	0.18	1.05	0.83	0.90	0.36	0.45
C ₅	0.07	0.01	0.29	0.52	0.12	0.88
C ₆	0.02	0.09	0.51	0.65	0.46	0.08
C ₇	3.73	3.90	3.91	3.98	3.71	3.71

C ₈	0.16	0.14	0.36	0.51	0.02	0.80
C ₉	0.05	0.16	0.45	0.37	0.63	0.74
C ₁₀	0.08	0.33	0.54	0.15	0.03	0.67
C ₁₁	0.08	0.02	0.28	0.46	0.14	0.76
C ₁₂	0.04	0.11	0.34	0.35	0.07	0.80
C ₁₃	-0.75	-0.15	-1.11	-1.11	-0.61	0.20
C ₁₄	0.12	0.04	0.50	0.67	0.14	0.52
C ₁₅	0.14	0.04	0.51	0.73	0.07	0.51
C ₁₆	0.28	0.03	0.50	0.89	0.23	0.69
C ₁₇	0.04	-0.04	-0.03	-0.04	0.02	0.19
C ₁₈	-3.10	-2.69	-3.69	-2.73	-2.81	-2.35
C ₁₉	-0.38	-0.07	-0.53	-0.45	-0.50	-0.13
C ₂₀	-0.21	-0.01	-0.34	-0.25	-0.31	-0.04
C ₂₁	0.11	-0.04	-0.03	0.06	0.18	0.10
C ₂₂	-0.48	-0.17	-0.94	-0.60	-0.43	-0.20
C ₂₃	-0.40	-0.08	-0.68	-0.41	-0.34	-0.14
C ₂₄	-1.59	-0.96	-2.25	-1.60	-1.53	-0.65

GPCR: G-protein coupled receptors.

Absorption, Distribution and Elimination Properties: Absorption, distribution and elimination properties of all the 24 Compounds [C₁-C₂₄] were predicted by using PreADMET and data were listed in **Table 4**. Compound C₁-C₂₄ showed %HIA ranging from 75-100, CaCO₂ cell permeability from 22-57, and skin permeability

from 1.72-4.49 cm/s. All the compounds are strongly bound to about 35-100 % plasma protein. Some chemical constituents showed P-glycoprotein I ranging from 38-100 %. Compounds C₃, C₆, C₇, C₁₈, C₂₄ do not cross the blood-brain barrier [BBB] as their permeability is nearly 0.1; the compounds C₂, C₂₀, C₂₃, C₂₅ penetrate BBB.

TABLE 4: ABSORPTION, DISTRIBUTION AND ELIMINATION PROPERTIES OF COMPOUNDS C₁-C₂₄

Compound Code	CaCO ₂ Permeability	MDCK	HIA	Skin Permeability	BBB	% PPB	P-gp
C ₁	32.13	72.66	100.00	-1.48	13.52	100.0	I
C ₂	57.70	56.53	100.00	-2.15	21.24	100.0	I
C ₃	15.59	0.043	94.60	-4.49	0.064	95.80	I
C ₄	49.25	0.043	97.83	-3.20	3.93	92.38	I
C ₅	57.81	58.26	100.00	-2.32	23.18	100.0	I
C ₆	51.57	357.69	94.74	-3.18	0.715	47.21	NI
C ₇	53.05	3.470	97.45	-3.71	0.72	52.92	NI
C ₈	22.20	66.19	100.00	-1.02	16.63	100.0	I
C ₉	22.2	66.02	100.00	-1.12	16.53	100.0	I
C ₁₀	49.25	0.043	97.83	-3.20	3.93	92.37	I
C ₁₁	38.19	115.8	100.00	-2.34	3.43	93.32	I
C ₁₂	48.56	0.04	98.49	-2.21	8.75	96.45	I
C ₁₃	27.87	153.2	100.00	-1.72	2.19	100.0	NI
C ₁₄	23.64	112.4	100.00	-1.08	9.58	100.0	I
C ₁₅	23.40	67.45	100.00	-1.42	18.19	100.0	I
C ₁₆	22.2	66.51	100.00	-1.14	16.95	100.0	I
C ₁₇	29.31	72.90	95.32	-0.56	10.40	100.0	I
C ₁₈	1.06	122.3	85.33	-0.40	0.32	66.82	NI
C ₁₉	22.19	67.97	100.00	-0.52	25.13	100.0	I
C ₂₀	22.19	66.02	100.00	-0.49	25.52	100.0	I
C ₂₁	40.79	68.44	95.34	-0.52	19.25	100.0	I
C ₂₂	22.19	66.77	100.00	-0.58	16.42	100.0	I
C ₂₃	22.19	67.91	100.00	-0.54	20.44	100.0	I
C ₂₄	1.85	24.09	75.91	-4.75	0.27	38.43	I

MDCK- madin-darby canine kidney, HIA- Human intestinal absorption, P-gp- Plasma glycoprotein, I- Inhibitor, NI- Non-Inhibitor

Metabolism and Toxicity Profile: CYP450 enzymes metabolize most medications; the most important of these enzymes are CYP2C9, CYP2C19, and CYP3A4. Metabolism and toxicity of compound C₁-C₂₄ were reported in **Table 5**. All the compounds except C₆ acts as I for the enzyme

CYP2C9, CYP2C19, CYP2D6 and CYP3A4, respectively and C₁, C₁₇, C₂₁ compounds displayed the all types of CYP2C,2D and 3A4 enzyme inhibition.

Mutagenicity was predicted to all the compounds by using the AMES test. Among all these 24

compounds C₁, C₃, C₈, C₉, C₁₁, C₁₆, C₁₉, C₂₀, C₂₁, C₁₇ do not exhibited mutagenicity. All the constituents have low to medium risk associated with HERG inhibition.

TABLE 5: METABOLISM AND TOXICITY PROPERTIES OF COMPOUNDS C₁-C₂₄

Compound Code	CYP2C19	CYP2C9	CYP2D6	CYP3A4	AMES mutagen	HERG inhibition
C ₁	I	I	I	I	No	LR
C ₂	NI	I	NI	I	Yes	MR
C ₃	NI	I	NI	I	No	LR
C ₄	NI	I	NI	I	Yes	LR
C ₅	NI	I	I	I	Yes	MR
C ₆	NI	NI	NI	NI	Yes	LR
C ₇	I	I	NI	I	Yes	LR
C ₈	NI	I	NI	I	No	MR
C ₉	NI	I	NI	I	No	MR
C ₁₀	NI	I	NI	I	Yes	LR
C ₁₁	NI	I	NI	I	No	LR
C ₁₂	NI	I	NI	I	Yes	LR
C ₁₃	NI	I	NI	I	Yes	MR
C ₁₄	NI	I	NI	I	Yes	LR
C ₁₅	NI	I	NI	NI	No	LR
C ₁₆	NI	I	NI	I	No	MR
C ₁₇	I	I	I	I	No	LR
C ₁₈	I	I	NI	I	Yes	LR
C ₁₉	I	I	NI	I	No	MR
C ₂₀	I	I	NI	I	No	MR
C ₂₁	I	I	I	I	No	LR
C ₂₂	I	I	NI	I	Yes	MR
C ₂₃	I	I	NI	I	Yes	MR
C ₂₄	NI	I	NI	NI	Yes	LR

CYP- cytochrome P 450 class of enzymes, LR-Low risk, MR- Medium risk.

CONCLUSION: The various computational tools used to predict molecular properties, Bioactivity scores, ADMET properties of the 24 chemical constituents [C₁-C₂₄] of *calotropis* species were selected based on their structure availability from pub chem databases and from articles published in journals. All the structures were drawn by using a chem sketch. Chemical constituents C₁-C₂₄ obeyed Lipinski's rule of five and exhibited good oral bioavailability. All compounds displayed moderate to high bioactivity scores towards the GPCR ligand, ion channel modulator, kinase, and protease enzymes. Among all, only 19 compounds showed BBB penetration. Except C₃, C₄, C₁₀, C₁₂ remaining compounds are sensitive to MDCK, indicating good renal absorption. Mostly all the compounds C₁, C₂, C₅, C₈, C₉, C₁₁, C₁₃, C₁₄, C₁₅, C₁₆, C₁₉, C₂₀, C₂₂, C₂₃ possess 100% human intestinal absorption. All the compounds having CaCO₂ permeability and C₁, C₂, C₅, C₈, C₉, C₁₃, C₁₄, C₁₅, C₁₆, C₁₉, C₂₀, C₂₁,

C₂₂, C₂₃ having 100% plasma protein binding. All the compounds except C₆, C₇, C₁₃, C₁₈ are P-gp inhibitors, indicating that the duration of action increases. Few compounds exhibited mutagenicity with AMES test and low to high risk produced with HERG inhibition.

ACKNOWLEDGEMENT: Authors are very thankful to the chairman P. Kanakaraju, coordinator P. Srinivas, Principal Dr. M. Trinadha Rao, Adarsa College of Pharmacy, G. Kothapalli for providing facilities to complete the work.

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Sharma A, Pooja S and Rima D: Herbal medicine -an introduction to its history. Herbal Medicine in Andrology 2021.
2. Hassan H M, Taha H M, Olayinka O, Idris H M, Omonike O S, Tosin Y A and Abimbola KO: Traditional herbal

- medicine: overview of research indexed in the scopus database. *Advances in Traditional Medicine* 2022.
3. Wachtel-galor S and Benzie IFF: Herbal medicine- An introduction to its history, usage, regulation, Current trends and research need. Boca raton (FL): CRC Presstaylor & Francis, Second Edition 2011.
 4. Rochester U: A guide to common medicine: Newyork. UR Medicine 2022.
 5. Zahid: Introduction and importance of medicinal plants and herbs: India. National Health Portam 2016.
 6. Ekins S, Mestres and Testa B: *In-silico* pharmacology for drug discovery: methods for virtual ligand screening and profiling. *British J of Pharmacology* 2009; 152(01): 9-20.
 7. Mohammad M, Reza G and Ali N: A contemporary review on the important role of in-silico approaches for managing different aspects of covid-19 crisis. *Informatics in Medicine Unlocked* 2022; 28: 100862.
 8. Sieburg HB: Physiological studies *in-silico*. *Studies in the Sciences of Complexity* 1990; 12: 321-342.
 9. Danchin A, Medigue C, Gascuel O, Soldano H and Henaut A: From data banks to databases. *Research in Microbiology* 1992; 142: 913-916.
 10. Danchin A and Quayle A Meyer: *The Delphic Boat -what Genomes tell us*. Harvard University Press: Cambridge, MA 2002; 422(6932): 564-564.
 11. Suresh Kumar P, Suresh E and Kalavathy S: Review on a potential herb *Calotropis gigantea* (L.) R. Br. *Scholar Academy Journal of Pharmacy* 2013; 2(2): 135-143.
 12. Sarkars, Raja Chakravarty and Ghosh A: *Calotropis gigantea* linn. – A complete Basket of Indian traditional medicine. *Int J of Pharma Res and Scie* 2014; 02(1): 7-17.
 13. Ali Esmail Al- Snafi: The constituents and pharmacological properties of *Calotropis procera* – an overview. *International Journal of Pharmaceutical sciences Review and Research* 2015; 5(3): 259-275.
 14. Abdulrahman MD: A systematic review on the biological evaluation of *Calotropis procera* (aiton) dryand. *Future Journal of Pharmaceutial Sciences* 2023; 9(16): 1-9.
 15. Moradi Md and Reza Gol Md: A contemporary review on the important role of *in-silico* approaches for managing different aspects of COVID-19 crisis. *Informatics in Medicine Unlocked* 2022; 28: 100862.
 16. Shashank Shekhar M, Neeraj Kumar, Pratap Singh H, Shashi R and Chandra Shekar S: *In-silico* pharmacokinetic, bioactivity and toxicity study of some selected anti-asthmatic agents. *Inte J of Pharmaceutical Sciences and Drug Research* 2018; 10(4): 278-282.
 17. Nur Aziz, Mi-yeon Kim and Jae Youlcho: Anti-inflammatory effects of luteolin: A review of *in-vitro* and *in-vivo* and *in-silico* studies. *Journal of Ethnopharmacology* 2018; 225: 342-358.
 18. Sri Mounika, Mounika T, Vidya Rani M and Rajitha G: Design and *in-silico* studies of molecular properties and bioactivity and toxicity of N-(A-Cyano substituted cinnamoyl)-2- Biphenyl hydrazone Derivatives. *Journal of Cardiovascular Disease Research* 2021; 12(06): 584-593.
 19. Radha R, Nivya P, Mounika T, Bharathi K and Bala Sree K: *In-silico* studies of heterocyclic derivatives as COX-2 inhibitors. *International Journal of Current Sciences PUB* 2022; 12(4): 2250-1770.
 20. Lemessa E B, Gemechu B T, Kim G, Kwon O and Lee D: In-silico activity and ADMET profiling of phytochemicals from Ethiopian indigenous aloes using pharmacophore models. *Scientific Reports* 2022; 12: 1-19.
 21. Vivek S, Ankush Y and Paratpar S: Molecular docking and ADMET study of bioactive compounds of *Glycyrrhiza glabra* against main protease of SARS-CoV2. *Materials Today: Proceedings* 2020; 49: 2999-3007.
 22. Sudha K, Rani S and Vishwanath BA: *In-silico* molecular docking and ADME /T analysis of some selected compounds of *Lepisanthes tetraphylla* (vahl) radlk against type 2 diabetes mellitus. *International Journal of Biology, Pharmacy and Allied Sciences* 2020; 9(8): 1963-1970.
 23. Rahman MM, Islam MR and Akash S: *In-silico* investigation and potential therapeutic approaches of natural products for covid-19: computer-aided drug design prospective. *Frontiers in Cellular and Infection Microbiology* 2022; 12: 929430.

How to cite this article:

Tummalapalli M, Appala VVS, Gundugolanu S, Komarapu K, Rao MT and Nagamani G: *In-silico* studies on chemical constituents of *Calotropis* species. *Int J Pharm Sci & Res* 2023; 14(8): 3935-41. doi: 10.13040/IJPSR.0975-8232.14(8).3935-41.

All © 2023 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)